India: MSF supports people living with HIV to oppose ViiV’s attempt to get patents for HIV drugs

The international medical humanitarian organization Médecins Sans Frontières (MSF) has expressed solidarity with the people living with HIV who are opposing the patent applications in India for two important HIV medicines, dolutegravir and cabotegravir. These patent oppositions have been filed to challenge an attempt by ViiV Healthcare (a joint venture by Pfizer and GlaxoSmithKline) to obtain monopoly rights in India while several of its patent claims are questionable according to Indian patentability criteria....In a statement, ViiV Healthcare spokesperson said, "We believe that our access to medicines strategy addresses the needs of people living with HIV in India. In 2013 we signed separate agreements with the Medicines Patent Pool (MPP) and Aurobindo to ensure access to our innovative antiretroviral medicines and combinations, including dolutegravir, where the need is greatest”. 

Get RSS feed of these results

All components of this story

Article
10 February 2016

Details on Patent Opposition

Author: Médecins Sans Frontières

Read the full post here

Article
10 February 2016

India: ViiV Healthcare accused of blocking access to life-saving HIV drugs

Author: Pharmaletter

HIV-specialist company ViiV Healthcare, majority owned by UK pharma major GlaxoSmithKline (LSE: GSK), is facing opposition in India to two patent applications it has submitted for dolutegravir (trade name Tivicay) and cabotegravir...The protestors claim that by securing the patents, ViiV Healthcare would block open generic competition among Indian producers and prevent thousands of patients from accessing life-saving medicine...a spokesperson for Viiv Healthcare said: "We believe that our access to medicines strategy addresses the needs of people living with HIV in India. In 2013 we signed separate agreements with the Medicines Patent Pool (MPP) and Aurobindo to ensure access to our innovative antiretroviral medicines and combinations, including dolutegravir, where the need is greatest. 

Article
10 February 2016

Pharma company ViiV’s attempt to secure patents for key HIV drugs dolutegravir and cabotegravir opposed in India

Author: Médecins Sans Frontières

People living with HIV have opposed patent applications in India for two important HIV medicines, dolutegravir and cabotegravir.  Médecins Sans Frontières/ Doctors Without Borders (MSF) supports these ‘patent oppositions,’ which have been filed to challenge an attempt by ViiV Healthcare (a joint venture by Pfizer and GlaxoSmithKline) to obtain monopoly rights in India while several of its patent claims are questionable according to Indian patentability criteria...“Patents for these drugs would mean complete monopoly status for a company which has already restricted the availability of an important HIV drug in India,” said Leena Menghaney, Head of MSF’s Access Campaign in South Asia.

 

Read the full post here